Measurable Residual Disease in Acute Lymphoblastic Leukemia: Techniques and Therapeutic Utility

H&O Is testing for measurable residual disease (MRD) now a standard component of management of patients with acute lymphoblastic leukemia (ALL)? LM Measurement of MRD is […]

Clinical Significance and Management of MRD in Adults With Acute Lymphoblastic Leukemia

Abstract: Measurable residual disease (MRD) quantification is an essential component of caring for patients with acute lymphoblastic leukemia (ALL). Many studies in pediatric and adult […]

Inotuzumab Ozogamicin, a Nonchemotherapy Option for Relapsed Acute Lymphoblastic Leukemia

H&O What percentage of patients with ALL will develop relapsed disease, and what is their prognosis? HK Among adult and elderly patients with acute lymphoblastic […]

Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia

Abstract: Patients with relapsed or refractory acute lymphoblastic leukemia (R/R ALL) have dismal outcomes, with survival of less than 6 months, and treatment options in […]

Tisagenlecleucel in Pediatric Patients With Acute Lymphoblastic Leukemia

H&O What is tisagenlecleucel? SM Tisagenlecleucel (Kymriah, Novartis) is an engineered T-cell therapy that uses a chimeric antigen receptor (CAR) to redirect the cytotoxic machinery […]

Management of Acute Lymphoblastic Leukemia in Young Adults

Abstract: Substantial interest in acute lymphoblastic leukemia (ALL) in young adults (YAs) and investigations focused on this patient population have resulted in therapeutic advancements that […]

Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia: Progress in a New Cancer Subtype

Abstract: Philadelphia chromosome–like (Ph-like) acute lymphoblastic leukemia (ALL) is a newly described, high-risk subtype of B-cell ALL. It is characterized by a gene expression profile […]

CD19-Targeted CAR T Cells as Novel Cancer Immunotherapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Clinical Advances in Hematology & Oncology October 2016, Volume 14, Issue 10 Marco L. Davila, MD, PhD, and Renier J. Brentjens, MD, PhD Dr Davila is […]